Endocrine Abstracts

Introduction: Nowadays, Diabetic nephropathy (DN) has become one of the leading causes of end-stage kidney disease.

Aim: The aim of our study was to determine the prevalence of diabetic nephropathy and to investigate its association with other comorbidities associated with diabetes.

Methods: A retrospective descriptive study was performed on 369 diabetic patients hospitalized in the c nutrition and metabolic diseases department. The definition as well as the different stages of diabetic nephropathy have been retained referring to the recommendations of the American Diabetes Association (ADA) of 2022.

Results: The median age of patients was 56.43 ±15.7 years old. The majority of patients in our study has type 2 diabetes (65.6%). The average duration of development of diabetes is 11 years. The prevalence of DN was 42.8% (29.1% stage 1; 8.2% stage 3; 2.1% stage 2; 2.5% stage 4 and 0.9% stage 5). Among them 31.3% has microalbuminuria and 11.5% has macroalbuminuria. High blood pressure is noted in 58.3% of patients with DN. High fasting blood glucose values as well as glycated hemoglobin outside the targets were noted in 78% of patients with DN. In our study a significant correlation was found between DN and diabetic retinopathy (P<10-3), dyslipidemia (P=0.004) and the duration of diabetes (P<10-3). Nevertheless, there were no significant differences in age(P=0.283) sex (P=0.277) and type of diabetes (P=0.725) between those with and without DN.

Conclusion: The prevention of the Diabetes kidney disease is a global challenge based on early detection to limit the progression to terminal kidney disease.